# **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

# **National Institutes of Health**

# National Institute of Mental Health; **Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of an Interagency Autism Coordinating Committee (IACC)

The purpose of the IACC meeting is to continue discussing recommendations for the annual update of the IACC Strategic Plan for Autism Spectrum Disorders Research. The IACC meeting will be conducted and available to the public via a telephone conference call and a webinar.

Name of Committee: Interagency Autism Coordinating Committee (IACC)

Type of meeting: Open meeting via conference call and webinar only; no inperson meeting.

Date: December 11, 2009.

Time: 9 a.m. to 1 p.m.\* Eastern Time-\* Approximate end time.

Meeting Registration: No registration is required to listen to the conference call or view the webinar.

Agenda: To continue discussion on recommendations for the annual update of the IACC Strategic Plan for Autism Spectrum Disorder Research.

Webinar: https://www2.gotomeeting.com/ register/906979171.

Conference Call Access: Dial: 888–455– 2920. Access code: 9984461.

Contact Person: Ms. Lina Perez, Office of Autism Research Coordination, Office of the Director, National Institute of Mental Health, NIH, 6001 Executive Boulevard, NSC, Room 8200, Bethesda, MD 20892-9669, Phone: (301) 443-6040, E-mail:

IACCPublicInquiries@mail.nih.gov.

Any interested person may submit written comments to the IACC prior to the meeting by sending the statement to the Contact Person listed on this notice by 5 p.m. ET on December 8, 2009. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. All written statements received by the deadline will be provided to the IACC for their consideration.

The meeting will be open to the public through a conference call phone number and a webinar conducted using a web presentation tool on the Internet. Individuals who participate using this service and who need special assistance, such as captioning of the conference call or other reasonable accommodations, should submit a request to the contact person listed above at least seven days prior to the meeting. If you experience any technical problems with the Web presentation tool or conference call, please

IACCTechSupport@acclaroresearch.com. Members of the public who participate using the conference call phone number will

be able to listen to the meeting but will not be heard. This phone call may end prior to or later than 1 p.m., depending on the needs of the Committee.

To access the webinar on the Internet the following computer capabilities are required: (A) Internet Explorer 5.0 or later, Netscape Navigator 6.0 or later or Mozilla Firefox 1.0 or later: (B) Windows® 2000, XP Home, XP Pro, 2003 Server or Vista; (C) Stable 56k, cable modem, ISDN, DSL or better Internet connection; (D) Minimum of Pentium 400 with 256 MB of RAM (Recommended); (E) Java Virtual Machine enabled (Recommended)

This meeting is being published less than 15 days prior to the meeting due to the timing limitations for completing the updating of the Annual Strategic Plan for Autism Spectrum Disorder Research.

Information about the IACC is available on the Web site: http://www.iacc.hhs.gov.

Meeting schedule subject to change.

Dated: November 19, 2009.

# Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-28284 Filed 11-24-09; 8:45 am]

BILLING CODE 4140-01-P

# **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

#### National Institutes of Health

# National Institute of Arthritis and Musculoskeletal and Skin Diseases; **Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Clinical Trial Grant Review.

Date: December 8, 2009.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

*Place*: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Eric H. Brown, PhD, Scientific Review Officer, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, 6701

Democracy Blvd., Room 824, Msc 4872, Bethesda, MD 20892-4872, (301) 594-4955,browneri@mail.nih.gov.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Providing Radiologic Outcomes for the Osteoarthritis Initiative.

Date: December 16, 2009.

Time: 10 a.m. to 11:30 a.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Charles N. Rafferty, PhD, Chief, Review Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, 6701 Democracy Boulevard, Suite 800, Bethesda, MD 20817, 301-534-4952, raffertycn@mail.nih.gov.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Clinical Outcome Instrument Development.

Date: January 26, 2010.

Time: 8 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Michael L. Bloom, PhD., MBA, Scientific Review Officer, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, 6701 Democracy Blvd.; Room 820, MSC 4872, Bethesda, MD 20892-4872, 301-594-4953, Michael Bloom@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research; 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: November 19, 2009.

# Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-28289 Filed 11-24-09; 8:45 am] BILLING CODE 4140-01-P

# **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

# **National Institutes of Health**

# National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Plasmodium Vivax and Malaria Research.

Date: December 16, 2009.

Time: 10:30 a.m. to 12:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Eleazar Cohen, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 6700B Rockledge Drive, Room 3129, Bethesda, MD 20892, 301–435–3564, ec17w@nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Innate Immunity.

*Date:* December 17, 2009. *Time:* 12 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Priti Mehrotra, Ph.D., Chief, Immunology Review Branch, Scientific Review Program, DEA/NIAID/NIH/DHHS, 6700B Rockledge Drive, Room 3138, Bethesda, MD 20892–7616, 301–435–9369, pm158b@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 19, 2009.

# Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–28286 Filed 11–24–09; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# **National Institutes of Health**

# Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose

confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: Molecular and Cellular Neuroscience.

Date: December 15, 2009. Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Jonathan K. Ivins, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040A, MSC 7806, Bethesda, MD 20892. (301) 594– 1245. ivinsj@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 18, 2009.

# Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–28276 Filed 11–24–09; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HOMELAND SECURITY

# **U.S. Customs and Border Protection**

Agency Information Collection Activities: Application To Establish a Centralized Examination Station

**AGENCY:** U.S. Customs and Border Protection, Department of Homeland Security.

**ACTION:** 30-Day notice and request for comments; Extension of an existing information collection: 1651–0061.

**SUMMARY: U.S. Customs and Border** Protection (CBP) of the Department of Homeland Security has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act: Application to Establish a Centralized Examination Station (CES). This is a proposed extension and revision of an information collection that was previously approved. CBP is proposing that this information collection be extended with no change to the burden hours. This document is published to obtain comments from the

public and affected agencies. This proposed information collection was previously published in the **Federal Register** (74 FR 48280) on September 22, 2009, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.10.

**DATES:** Written comments should be received on or before December 28, 2009.

ADDRESSES: Interested persons are invited to submit written comments on this proposed information collection to the Office of Information and Regulatory Affairs, Office of Management and Budget. Comments should be addressed to the OMB Desk Officer for Customs and Border Protection, Department of Homeland Security, and sent via electronic mail to oira\_submission@omb.eop.gov or faxed to (202) 395–5806.

# SUPPLEMENTARY INFORMATION:

U.S. Customs and Border Protection (CBP) encourages the general public and affected Federal agencies to submit written comments and suggestions on proposed and/or continuing information collection requests pursuant to the Paperwork Reduction Act (Pub. L. 104–13). Your comments should address one of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency/component, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agencies/components estimate of the burden of The proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collections of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological techniques or other forms of information.

Title: Application to Establish Centralized Examination Station. OMB Number: 1651–0061. Form Number: None.

Abstract: If a port director decides his or her port needs a Centralized Examination Station (CES), the port director announces this need to the public and solicits applications to operate a CES. The information contained in the application will be used to determine the suitability of the applicant's facility, the fairness of his